Hypogammaglobulinemia is an expected on-target-off-tumor toxicity of BCMA-directed therapies given BCMA expression on normal and malignant plasma cells [1]. This evidence concerns the gene TNFRSF17 and Decreased circulating immunoglobulin concentration.